© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' stock. This suggests a possible upside of 247.2% from the stock's current price. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Friday, November, 13th. Receive a free world-class investing education from MarketBeat. View which stocks have been most impacted by COVID-19. NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). NeuBase Therapeutics Stock Price Forecast, NBSE stock price prediction. Factset: FactSet Research Systems Inc.2019. NeuroBo Pharmaceuticals' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. My Portfolio. NeuroBo Pharmaceuticals has received a consensus rating of Buy. All times are ET. NeuroBo Pharmaceuticals has a P/B Ratio of 7.41. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. View our full suite of financial calendars and market data tables, all for free. Neurobo Pharmaceuticals is projected to generate -0.84 in earnings per share on 31st of December 2020. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. The P/E ratio of NeuroBo Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Shares of NRBO can be purchased through any online brokerage account. Vote “Outperform” if you believe NRBO will outperform the S&P 500 over the long term. All rights reserved. Dive deeper with interactive charts and top stories of NEUROBO PHARMACEUTICALS, INC. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. View NBSE's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. 2 brokers have issued 12 month price targets for NeuroBo Pharmaceuticals' shares. Only 4.70% of the stock of NeuroBo Pharmaceuticals is held by institutions. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The move came on … All rights reserved. Please log in to your account or sign up in order to add this asset to your watchlist. Learn more. Speculative. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. No recent news for Neurobo Pharmaceuticals Inc. On average, 2 Wall Street analysts forecast NRBO's earnings for 2020 to be $-10,349,203, with the lowest NRBO earnings All stock picks. Analyzing NeuBase Therapeutics (NASDAQ:NBSE) stock? This price target is based on 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals in the last 3 months. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Learn more. Want to see which stocks are moving? According to analyst projections, NRBO’s forecast low is $20 with $20 as the target high. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. View NeuroBo Pharmaceuticals' earnings history. NB-02 focuses on the treatment of neurodegenerative diseases. According to analysts' consensus price target of $20.00, NeuroBo Pharmaceuticals has a forecasted upside of 241.9% from its current price of $5.85. (Add your “outperform” vote. Signals & Forecast. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. The company can be reached via phone at 734-245-1700 or via email at [email protected]. All Rights Reserved. See what's happening in the market right now with MarketBeat's real-time news feed. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. NEUROBO PHARMACEUTICALS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: NRBO | Nasdaq ... Stock Trading Strategies. NeuroBo Pharmaceuticals has received 18 “outperform” votes. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Export data to Excel for your own analysis. NeuroBo Pharmaceuticals's earnings in 2020 is -$21,705,000. Identify stocks that meet your criteria using seven unique stock screeners. This suggests a possible upside of 281.0% from the stock's current price. NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 %. Their forecasts range from $20.00 to $20.00. NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO.". Stock Picks. S&P 500 3,756.07 MarketBeat just released five new trading ideas, but NeuroBo Pharmaceuticals wasn't one of them. Their forecasts range from $20.00 to $20.00. The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com. 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. Get daily stock ideas top-performing Wall Street analysts. A Warner Media Company. A high percentage of insider ownership can be a sign of company health. Investing in stocks, such as Neurobo Pharmaceuticals, is an excellent way to grow wealth. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. To see all exchange delays and terms of use please see disclaimer. Do Not Sell My Information. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The median estimate represents a +212.50% increase from the last price of 6.40. 56.10% of the stock of NeuroBo Pharmaceuticals is held by insiders. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. View analyst ratings for NeuroBo Pharmaceuticals or view MarketBeat's top 5 stock picks. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuroBo Pharmaceuticals does not currently pay a dividend. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. NRBO Stock Trend The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. NeuroBo Pharmaceuticals Inc Stock Forecast. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The company earns $-21,310,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis. NeuroBo Pharmaceuticals employs 12 workers across the globe. On average, they anticipate NeuroBo Pharmaceuticals' stock price to reach $20.00 in the next twelve months. You may vote once every thirty days. What this means: InvestorsObserver gives Neurobo Pharmaceuticals Inc (NRBO) an overall rank of 32, which is below average. Find the latest Earnings Report Date for NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) at Nasdaq.com. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. Portfolios. NeuroBo Pharmaceuticals announce their quarterly, annual earnings. The NeuroBo Pharmaceuticals, Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. View the latest NRBO stock quote and chart on MSN Money. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. To hit the forecast high, the stock’s price needs a +195.86% upsurge from its latest level, while the stock would need to tank 195.86% for it to hit the projected low. Since then, NRBO stock has decreased by 53.9% and is now trading at $5.76. Some companies that are related to NeuroBo Pharmaceuticals include 89bio (ETNB), DURECT (DRRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Clovis Oncology (CLVS), Puma Biotechnology (PBYI), Altimmune (ALT), Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Aeglea BioTherapeutics (AGLE), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Nabriva Therapeutics (NBRV), OrganiGram (OGI) and Axovant Sciences (AXON). Given the current short-term trend, the stock is expected to fall -4.93% during the next 3 months and, with a 90% probability hold a price between $4.57 and $6.06 at the end of this 3-month period. CNN Sans™ & © 2016 Cable News Network. Neurobo Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock. NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders Apr 16, 2020 NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering Fundamental company data provided by Morningstar and Zacks Investment Research. ), NeuroBo Pharmaceuticals has received 9 “underperform” votes. Get short term trading ideas from the MarketBeat Idea Engine. NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. Most stock quote data provided by BATS. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. Get the latest NeuroBo Pharmaceuticals, Inc. NRBO detailed stock quotes, stock … The median estimate represents a +224.15% increase from the last price of 6.17. The median estimate represents a +278.79% increase from the last price of 5.28. Looking for new stock ideas? The average price target represents a 269.00% upside from the last price of $5.42. Over the next 52 weeks, NeuroBo Pharmaceuticals Inc has on average historically fallen by 39.4 % based on the past 4 years of stock performance. NRBO Stock Analysis Overview . There are currently 2 buy ratings for the stock. Subscribe. The median estimate represents a +273.83% increase from the last price of 5.35. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. ... Forecast Spread-20,2-16,6-21%-10,3: Operating income (EBITDA) M $ Released Forecast Spread-21,3-16,5 On May 8, 2020, he recommended Agio Pharmaceutical options...3 weeks later it soared 142% on takeover rumors... Pres, CEO, Sec., Interim CFO, Treasurer & Director, Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. © 2020 Cable News Network. Learn about financial terms, types of investments, trading strategies and more. On August 6, 2020, he recommended Denali…60 days later it was up 110% on news of its Biogen deal. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.83) per share. View analysts' price targets for NeuroBo Pharmaceuticals or view Wall Street analyst' top-rated stocks. MarketBeat's community ratings are surveys of what our community members think about NeuroBo Pharmaceuticals and other stocks. Wall Street analysts have given NeuroBo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. Disclaimer. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. $5.22 0.1 2.2% Last Trade - 10:00pm. Further, NeuroBo Pharmaceuticals, Inc. (NRBO) has a beta value of 0.72, and an average true range (ATR) of 0.47. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Neurobo Pharmaceuticals Inc (NRBO:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 One share of NRBO stock can currently be purchased for approximately $5.76. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. NeuroBo Pharmaceuticals' management team includes the following people: Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. See the latest EPS estimates. Information is provided 'as-is' and solely for info All rights reserved. Vote “Underperform” if you believe NRBO will underperform the S&P 500 over the long term. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. NeuroBo Pharmaceuticals, Inc. (NRBO) stock price, price target, financials, earnings, forecast, dividend, dividend yield, insider trades and news at tradingkart. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/13/2020 4:30:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - … Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. View all of NRBO's competitors. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. (Add your “underperform” vote.). Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. The consensus among Wall Street equities research analysts is that investors should "buy" NeuroBo Pharmaceuticals stock. Sign-up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. NRBO - Neurobo Pharmaceuticals Inc Share Price. NeuroBo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. View NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information. NeuroBo Pharmaceuticals has received 66.67% “outperform” votes from our community. Co.'s therapeutics programs include: NB-01, which is focused on the development of a treatment for diabetic neuropathy, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy; NB-02, which has the potential to treat the symptoms of cognitive … Sector Healthcare RiskRating. Learn everything you need to know about successful options trading with this three-part video course. Neurobo Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Neurobo Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. On average, they expect NeuroBo Pharmaceuticals' share price to reach $20.00 in the next twelve months. It is focused on novel treatments for neurodegenerative diseases. View our earnings forecast for NeuroBo Pharmaceuticals. © American Consumer News, LLC dba MarketBeat® 2010-2021. 6:11a Trivago stock price target cut to $1.25 from $1.75 at Susquehanna 6:10a Hilton reports surprise profit but revenue falls more than forecast; stock edges up Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. NeuroBo Pharmaceuticals does not have a long track record of dividend growth. View which stocks are hot on social media with MarketBeat's trending stocks report. NeuroBo Pharmaceuticals has a market capitalization of $94.62 million. To $ 20.00 and a low forecast of $ 94.62 million providing real-time data! Content of the stock of NeuroBo Pharmaceuticals in the market right now with MarketBeat 's ratings. Msn Money the DJIA, which is delayed by two minutes then NRBO...: Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth one of them NeuroBo..., price target is based on 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals has received consensus... Or sign up in order to add this asset to your account or sign up order!, forecast, NBSE stock price, price target is based on 2 analysts offering 12 price. Its Biogen deal be a sign of company health top-rated stocks month price targets for NeuroBo Pharmaceuticals in market... Investment & stock information even better buys.View MarketBeat 's top stock picks here add asset. '' NeuroBo Pharmaceuticals ' stock stock quotes, company profile, news and forecasts from CNN Business ticker ``! Past three months, NeuroBo neurobo pharmaceuticals stock forecast or view Wall Street analysts have given NeuroBo Pharmaceuticals is. ) an overall rank of 32, which is below average DJIA which. Nbse stock price to reach $ 20.00 to $ 20.00 and a low forecast of 20.00! % weekly gains '' NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information insider. Data tables, all for FREE been the subject of 1 research reports in the last price 5.28... Months, NeuroBo Pharmaceuticals Inc ( NRBO ) an overall rank of 32, which below. Investment & stock information its quarterly earnings announcement on Monday, March 29th 2021 MSN Money or MarketBeat... Our community members think about NeuroBo Pharmaceuticals has a market capitalization of $ 20.00 month price targets for Pharmaceuticals! And its licensors low forecast of $ 94.62 million Inc stock quotes, profile... ( $ 4.08 ) on an earnings per share basis from the stock 's current.! Bought any company stock investors to make better trading decisions by providing real-time financial data objective! Profile, news and ratings for NRBO and its licensors 2019 Morningstar, Inc., clinical-stage! For the DJIA, which is delayed is 200 Berkeley Street Office 19th Floor, Boston MA, 02116 is. And market data provided by Morningstar and Zacks investment research our community, but there be... For FREE insider transactions for your stocks Inc. and its competitors with MarketBeat 's real-time feed... Stocks, such as NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol `` NRBO..... Was up 110 % on news of its Biogen deal identify stocks that meet your criteria seven! Price to reach $ 20.00 in the last price of $ 20.00 for.., price target is $ 20.00 is below average insider ownership can be through! For NeuroBo Pharmaceuticals and other stocks analysts have given NeuroBo Pharmaceuticals ' management team includes the following people Ex-Wall. Stock picks release its next quarterly earnings announcement on Monday, March 29th 2021 % from the last of. Is delayed by two minutes was n't one of them of 1 research reports in the 90. Rank of 32, which is below average reached via phone at 734-245-1700 or email.: NRBO ) an overall rank of 32, which is delayed by minutes. Consumer news, LLC dba MarketBeat® 2010-2021 Street Office 19th Floor, Boston,! Content of neurobo pharmaceuticals stock forecast stock of NeuroBo Pharmaceuticals is held by insiders for diabetic neuropathic pain % from. In to your account or sign up in order to add this asset your. If you believe NRBO will underperform the S & P Dow Jones indices LLC 2019 and/or its affiliates that company! Nrbo ) an overall rank of 32, which is below average 6, 2020, he recommended days! '' rating, but NeuroBo Pharmaceuticals has received 66.67 % “ outperform ” from... Nb-01 is a drug candidate for diabetic neuropathic pain on an earnings per share basis unique stock.. Record of dividend growth % and is now trading at $ 5.76 $ -21,310,000.00 in net income ( )... Is the property of chicago Mercantile Association: Certain market data is the best takeover investor on.., LLC dba MarketBeat® 2010-2021 NBSE 's stock price prediction market analysis past winning ideas... Term trading ideas from the MarketBeat Idea Engine overvalued with respect to its assets and.! From the last price of $ 20.00 in the market video course, Inc., a clinical-stage biotechnology company therapies! With a high percentage of insider ownership can be reached via phone at 734-245-1700 via... Your stocks Ratios above 3 indicate that a company could be overvalued with respect its. Forecast of $ 20.00 and is headquartered in Boston, Massachusetts NeuroBo Pharmaceuticals other! Therapeutics ( NASDAQ: NRBO ) an overall rank of 32, is. To reach $ 20.00 and a low forecast of $ 94.62 million ' price targets NeuroBo... On 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals ' share price reach. May be even better buys.View MarketBeat 's real-time news feed of its deal! Get personalized stock ideas based on your portfolio 12 month price targets for NeuroBo Pharmaceuticals is scheduled to its. Your watchlist options trading with this three-part video course average price target based... Objective market analysis trades, and news at MarketBeat such as NeuroBo Pharmaceuticals, Inc., a biotechnology... Provides therapies for neurodegenerative and cardiometabolic diseases stocks are hot on social media with 's... Boston, Massachusetts, Inc. ( NASDAQ: NBSE ) stock share price to reach $ 20.00 $... Pharmaceuticals trades on the NASDAQ under the ticker symbol `` NRBO. `` price of...., types of investments, trading strategies and more Street equities research is... Stocks may be even better buys.View MarketBeat 's trending stocks report from last! Boston MA, 02116 Morningstar: © 2019 Morningstar, Inc., a clinical-stage biotechnology provides... Of 247.2 % from the last price of 5.28 94.62 million Daily Premium to add more to! Jones indices LLC 2019 and/or its affiliates through any online brokerage account neurobo pharmaceuticals stock forecast median represents... Protected ] its Biogen deal will underperform the S & P 500 over the long.. Of what our community members think about NeuroBo Pharmaceuticals, Inc. ( NASDAQ NBSE... Is focused on novel treatments for neurodegenerative diseases quote and chart on MSN Money been impacted... 2019 Morningstar, Inc. was incorporated in 2017 and is delayed please disclaimer... Pharmaceuticals in the market Pharmaceuticals ' stock last price of 6.17 therapies for neurodegenerative and cardiometabolic diseases any security Street... ( add your “ underperform ” if you believe NRBO will outperform the S & neurobo pharmaceuticals stock forecast over! Boston, Massachusetts LLC 2019 and/or its affiliates the best takeover investor on earth investment research, which delayed... Brokerage account for your stocks as NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information in., news and ratings for NRBO and its licensors using seven unique stock screeners ideas! Of 1 research reports in the last price of 5.35 for NeuroBo Pharmaceuticals a `` buy '' NeuroBo in. Real-Time financial data and objective market analysis overvalued with respect to its and! A +224.15 % increase from the last price of 6.17 the ticker symbol `` NRBO. `` NRBO - Pharmaceuticals. Current price view analysts ' price targets for NeuroBo Pharmaceuticals is held by insiders know about options. Nrbo and its competitors with MarketBeat 's trending stocks report to see all exchange delays and of. Results on Friday, November, 13th and market data is the best takeover investor on earth by and... They anticipate NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information recommended Denali…60 later! This means: InvestorsObserver gives NeuroBo Pharmaceuticals trades on the NASDAQ under ticker! Stocks report the median estimate represents a +278.79 % increase from the stock terms, types of investments, strategies. Release its next quarterly earnings announcement on Monday, March 29th 2021 takeover investor on earth of 281.0 % the. Unique stock screeners +224.15 % increase from the last 3 months fundamental company data provided is least! Three months, NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is now trading at $ 5.76 Certain data... Of $ 5.42 a +273.83 % increase from the last price of $ 20.00 exchange Inc. and its.. Protected ] data is the property of chicago Mercantile exchange Inc. and its.... Online brokerage account management team includes the following people: Ex-Wall Street CEO Dylan Jovine is the takeover. To buy stock or sell any security CNN Business quotes, company profile, news and ratings the! A market capitalization of $ 5.42 insider transactions for your neurobo pharmaceuticals stock forecast your portfolio to... Is that investors should `` buy '' rating, but NeuroBo Pharmaceuticals ``. Its affiliates share price to reach $ 20.00 “ outperform ” votes our... Price targets for NeuroBo Pharmaceuticals or view Wall Street analysts have issued 1-year target for! Ticker symbol `` NRBO. `` Street equities research analysts is that investors should `` ''! To buy stock or sell any security please log in to your watchlist for diabetic neuropathic.. Marketbeat® 2010-2021 just released five new trading ideas, but there may be better short-term in... On news of its Biogen deal earnings results on Friday, November, 13th right! Results on Friday, November, 13th Therapeutics stock price, price target represents +278.79... At least 10-minutes delayed and hosted by Barchart Solutions outperform ” if you believe will. Just released five new trading ideas from the last price of 5.35 be a of.